Denali has entered a $275m royalty funding agreement with Royalty Pharma based on future net sales of tividenofusp alfa ...

Hypersensitivity reactions in a mouse model prompted the agency to suspend Denali’s planned Phase I development for DNL952 ...

The FDA has placed a hold on Denali Therapeutics’ plans to launch a phase 1 rare disease trial, citing concerns about immune ...

In return, Royalty will receive a 9.25% royalty on worldwide sales of tividenofusp alfa from Denali until it reaches three times the amount Royalty has handed to Denali—or, alternatively, 2.5 times ...

In early December 2025, Denali Therapeutics announced a US$275 million synthetic royalty funding agreement with Royalty Pharma tied to future worldwide net sales of its investigational Hunter syndrome ...

One of the best aspects of our job is the wide variety of vehicles we get to test and evaluate.Driving supercars and off-road ...

Shares of US drug developer Denali Therapeutics closed up 5.8% at $20.11 yesterday, after it announced a $275 million ...

Denali National Park and Preserve is named for the nation’s mightiest mountain, but the 6-million-acre park encompasses so much more. Denali has options for every type of visitor. Whether you’re an ...

Investing.com -- Denali Therapeutics Inc (NASDAQ:DNLI) stock rose 5.7% on Thursday after the company announced a $275 million synthetic royalty funding agreement with Royalty Pharma plc (NASDAQ:RPRX) ...

Denali Therapeutics and Royalty Pharma entered a $275 million royalty funding agreement based on future sales of tividenofusp alfa.

NEW YORK and SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI) today announced a $275 million synthetic ...

As a Miami newspaper publisher, I’ve watched this city grow from a sun-splashed getaway to a global hub of culture, business, ...